Dr. Reddy’s AmVaz Approval Stayed; FDA Reconsiders Norvasc Competitor
Executive Summary
FDA's stay of Dr. Reddy's AmVaz suggests the agency is taking another look at the amlodipine maleate NDA to bolster its response to Pfizer's scientific argument against use of the 505(b)(2) approval pathway
You may also be interested in...
Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?
Watson filed a 505(b)(2) NDA for a zinc salt of AstraZeneca’s Crestor, which AstraZeneca claims infringes its patent; if Watson prevails more generic manufacturers may pursue this pathway around a patent.
505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney
FDA should develop standards for use of the 505(b)(2) approval pathway to better allow for predictability of its application, according to Pfizer Assistant General Council Jeffrey Chasnow
505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney
FDA should develop standards for use of the 505(b)(2) approval pathway to better allow for predictability of its application, according to Pfizer Assistant General Council Jeffrey Chasnow